central nervous system agents

Summary

Summary: A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "nonspecific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p252)

Top Publications

  1. ncbi Delivery of therapeutic agents to the central nervous system: the problems and the possibilities
    David J Begley
    Blood Brain Barrier Research Group, GKT School of Biomedical Science, Guy s Campus, King s College London, Hodgkin Building, London SE1 1UL, UK
    Pharmacol Ther 104:29-45. 2004
  2. ncbi Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
    Wolfgang Loscher
    Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Bunteweg 17, D 30559 Hannover, Germany
    Prog Neurobiol 76:22-76. 2005
  3. ncbi Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans
    Martin Brunner
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Institute of Medical and Chemical Laboratory Diagnostics, Vienna, Austria
    Clin Pharmacol Ther 78:182-90. 2005
  4. pmc Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery
    Mohammad S Alavijeh
    Pharmidex, London W1S 1RR, United Kingdom
    NeuroRx 2:554-71. 2005
  5. ncbi Active-site concentrations of chemicals - are they a better predictor of effect than plasma/organ/tissue concentrations?
    Margareta Hammarlund-Udenaes
    Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
    Basic Clin Pharmacol Toxicol 106:215-20. 2010
  6. ncbi Ginsenosides Rb1 and Rg1 effects on mesencephalic dopaminergic cells stressed with glutamate
    Khaled Radad
    Institute for Medical Chemistry, Veterinary Medical University, Veterinaerplatz 1, A 1210 Vienna, Austria
    Brain Res 1021:41-53. 2004
  7. ncbi Solid lipid nanoparticles for targeted brain drug delivery
    Paolo Blasi
    Department of Chemistry and Technology of Drugs, School of Pharmacy, University of Perugia, Via del Liceo 1, 06123 Perugia, Italy
    Adv Drug Deliv Rev 59:454-77. 2007
  8. ncbi Ginsenoside Rg1 promotes nonamyloidgenic cleavage of APP via estrogen receptor signaling to MAPK/ERK and PI3K/Akt
    Chun Shi
    Department of Anatomy, Guangzhou Medical University, Guangzhou 510182, China
    Biochim Biophys Acta 1820:453-60. 2012
  9. ncbi The role of imaging in proof of concept for CNS drug discovery and development
    Dean F Wong
    Johns Hopkins University School of Medicine, Johns Hopkins University School of Medicine, 601 North Caroline St, JHOC room 3245, Baltimore, MD 21287 0807, USA
    Neuropsychopharmacology 34:187-203. 2009
  10. pmc Central nervous system agents for ischemic stroke: neuroprotection mechanisms
    Rachna S Pandya
    Brigham and Women s Hospital, Harvard Medical School, Department of Neurosurgery, Boston, Massachusetts 02115, USA
    Cent Nerv Syst Agents Med Chem 11:81-97. 2011

Research Grants

  1. Neurotrophin Blood/Brain Barrier Delivery in Ischemia
    William Pardridge; Fiscal Year: 2006
  2. PTS1 Regulation of Brain Met Enk Levels in Alcoholism
    William Banks; Fiscal Year: 2004
  3. BLOOD BRAIN BARRIER LARGE NEUTRAL AMINO ACID TRANSPORTER
    William Pardridge; Fiscal Year: 2003
  4. Multiplexed flow cytometry screens for RGS inhibitors
    Richard Neubig; Fiscal Year: 2007
  5. AMPHETAMINE ENHANCED STROKE RECOVERY--BURKE SRCI GROUP
    Larry Goldstein; Fiscal Year: 2002
  6. STRUCTURAL BASIS OF RECEPTOR/G PROTEIN FUNCTION
    Richard Neubig; Fiscal Year: 2004
  7. Prion Transport Across the Blood-Brain Barrier
    William Banks; Fiscal Year: 2009
  8. Mechanisms of HIV Transport Across the BBB
    William Banks; Fiscal Year: 2004
  9. AIDS Neurotherapeutics and BBB Drug Efflux
    William Pardridge; Fiscal Year: 2007
  10. REGULATION OF BBB GLUT1 GLUCOSE TRANSPORTER
    William Pardridge; Fiscal Year: 2002

Detail Information

Publications240 found, 100 shown here

  1. ncbi Delivery of therapeutic agents to the central nervous system: the problems and the possibilities
    David J Begley
    Blood Brain Barrier Research Group, GKT School of Biomedical Science, Guy s Campus, King s College London, Hodgkin Building, London SE1 1UL, UK
    Pharmacol Ther 104:29-45. 2004
    ..The various strategies available and under development for enhancing drug delivery to the CNS are reviewed...
  2. ncbi Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
    Wolfgang Loscher
    Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Bunteweg 17, D 30559 Hannover, Germany
    Prog Neurobiol 76:22-76. 2005
    ..Finally, we summarize strategies for modulating or by-passing drug efflux transporters at the BBB as novel therapeutic approaches to drug-resistant brain diseases...
  3. ncbi Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans
    Martin Brunner
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Institute of Medical and Chemical Laboratory Diagnostics, Vienna, Austria
    Clin Pharmacol Ther 78:182-90. 2005
    ....
  4. pmc Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery
    Mohammad S Alavijeh
    Pharmidex, London W1S 1RR, United Kingdom
    NeuroRx 2:554-71. 2005
    ..This review focuses on BBB penetration, along with pharmacokinetics and drug metabolism, in the process of the discovery and development of safe and effective medicines for CNS disorders...
  5. ncbi Active-site concentrations of chemicals - are they a better predictor of effect than plasma/organ/tissue concentrations?
    Margareta Hammarlund-Udenaes
    Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
    Basic Clin Pharmacol Toxicol 106:215-20. 2010
    ..However, there is an urgent need to collect more relevant data for predicting active site concentrations in tissues with active transporters in their plasma membranes...
  6. ncbi Ginsenosides Rb1 and Rg1 effects on mesencephalic dopaminergic cells stressed with glutamate
    Khaled Radad
    Institute for Medical Chemistry, Veterinary Medical University, Veterinaerplatz 1, A 1210 Vienna, Austria
    Brain Res 1021:41-53. 2004
    ..Thus our study indicates that ginsenosides Rb1 and Rg1 have a partial neurotrophic and neuroprotective role in dopaminergic cell culture...
  7. ncbi Solid lipid nanoparticles for targeted brain drug delivery
    Paolo Blasi
    Department of Chemistry and Technology of Drugs, School of Pharmacy, University of Perugia, Via del Liceo 1, 06123 Perugia, Italy
    Adv Drug Deliv Rev 59:454-77. 2007
    ..A critical consideration on the potential application of such technology as related to the current status of brain drug development is also given...
  8. ncbi Ginsenoside Rg1 promotes nonamyloidgenic cleavage of APP via estrogen receptor signaling to MAPK/ERK and PI3K/Akt
    Chun Shi
    Department of Anatomy, Guangzhou Medical University, Guangzhou 510182, China
    Biochim Biophys Acta 1820:453-60. 2012
    ..However, it is unknown whether Rg1-induced estrogenic activity intervenes in APP processing, and improves memory performance...
  9. ncbi The role of imaging in proof of concept for CNS drug discovery and development
    Dean F Wong
    Johns Hopkins University School of Medicine, Johns Hopkins University School of Medicine, 601 North Caroline St, JHOC room 3245, Baltimore, MD 21287 0807, USA
    Neuropsychopharmacology 34:187-203. 2009
    ..In summary, this article reviews the vital biomarker approach of neuroimaging in proof of concept studies...
  10. pmc Central nervous system agents for ischemic stroke: neuroprotection mechanisms
    Rachna S Pandya
    Brigham and Women s Hospital, Harvard Medical School, Department of Neurosurgery, Boston, Massachusetts 02115, USA
    Cent Nerv Syst Agents Med Chem 11:81-97. 2011
    ..This review focuses on central nervous system agents targeting these biochemical pathways and mediators of ischemic stroke, mainly those that counteract ..
  11. pmc The blood-brain barrier and neurotherapeutics
    William M Pardridge
    NeuroRx 2:1-2. 2005
  12. pmc Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems
    Akira Tsuji
    Division of Pharmaceutical Sciences, Graduate School of Natural Science and Technology, Kanazawa University, Kakuma machi, Kanazawa 920 1192, Japan
    NeuroRx 2:54-62. 2005
    ....
  13. ncbi Ginsenoside Rg1 attenuates amyloid-beta content, regulates PKA/CREB activity, and improves cognitive performance in SAMP8 mice
    Yan Qing Shi
    Fujian Institute of Geriatrics, Fuzhou, Fujian, People s Republic of China
    J Alzheimers Dis 19:977-89. 2010
    ..These data provide further support for the therapeutic or intervention potency of ginsenoside Rg1 in the early stage of AD...
  14. ncbi Ginsenoside Rg1 attenuates β-amyloid generation via suppressing PPARγ-regulated BACE1 activity in N2a-APP695 cells
    Li Min Chen
    Department of Neurology, Fujian Institute of Geriatrics, the Affiliated Union Hospital of Fujian Medical University, People s Republic of China
    Eur J Pharmacol 675:15-21. 2012
    ..Therefore, ginsenoside Rg1 may serve as a promising agent in modulating Aβ-related pathology in Alzheimer's disease...
  15. ncbi Why is the global CNS pharmaceutical market so under-penetrated?
    William M Pardridge
    Drug Discov Today 7:5-7. 2002
  16. ncbi Measurement of the pharmacokinetics and pharmacodynamics of neuroactive compounds
    Mohammad S Alavijeh
    Pharmidex Pharmaceutical Services Ltd, 72 New Bond Street, London, W1S 1RR, UK
    Neurobiol Dis 37:38-47. 2010
    ....
  17. ncbi Ginsenosides Rg1 and Rb1 enhance glutamate release through activation of protein kinase A in rat cerebrocortical nerve terminals (synaptosomes)
    Yi Chang
    School of Medicine, Fu Jen Catholic University, 510, Chung Cheng Rd, Hsin Chuang, Taipei Hsien 24205, Taiwan
    Eur J Pharmacol 578:28-36. 2008
    ..This finding might provide important information regarding the action of ginseng in the central nervous system...
  18. ncbi Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain
    Jorg Kreuter
    Institut fur Pharmazeutische Technologie, Johann Wolfgang Goethe Universitat, Frankfurt, Marie Curie Strasse 9, D 60439 Frankfurt Main, Germany
    J Nanosci Nanotechnol 4:484-8. 2004
    ..quot; The drug, then, may be released either within these cells followed by passive diffusion into the brain or be transported into the brain by transcytosis...
  19. ncbi Ginsenoside Rb1 and Rg1 improve spatial learning and increase hippocampal synaptophysin level in mice
    I Mook-Jung
    Brain Disease Research Center, Ajou University School of Medicine, Suwon, Korea
    J Neurosci Res 63:509-15. 2001
    ..Our results suggest that Rb1 and Rg1 enhance spatial learning ability by increasing hippocampal synaptic density without changing plasticity of individual synapses...
  20. ncbi Central nervous system agents in the treatment of erectile dysfunction: how do they work?
    J Allard
    Department of Urology, CHU de Bicetre, 78 rue du General Leclerc, 94270 Le Kremlin Bicêtre cedex, France
    Curr Urol Rep 2:488-94. 2001
    ..Our knowledge of the mode of action of CNS drugs comes mainly from experiments on rodents. Consequently, explanations regarding the way they work in humans are only speculative...
  21. ncbi Ginsenoside-Rg1 induces vascular endothelial growth factor expression through the glucocorticoid receptor-related phosphatidylinositol 3-kinase/Akt and beta-catenin/T-cell factor-dependent pathway in human endothelial cells
    Kar Wah Leung
    Department of Biology, Hong Kong Baptist University, Kowloon Tong, Hong Kong, China
    J Biol Chem 281:36280-8. 2006
    ..In addition, the GR antagonist RU486 was able to inhibit Rg1-induced PI3K/Akt and beta-catenin activation. These findings provide new insights into the mechanism responsible for Rg1 functions...
  22. ncbi Getting into the brain: approaches to enhance brain drug delivery
    Mayur M Patel
    Institute of Pharmacy, Nirma University of Science and Technology, Ahmedabad, India
    CNS Drugs 23:35-58. 2009
    ..The current challenge is to develop drug delivery strategies that will allow the passage of drug molecules through the BBB in a safe and effective manner...
  23. ncbi Nanoparticle technology for drug delivery across the blood-brain barrier
    P R Lockman
    Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo 79106 1712, USA
    Drug Dev Ind Pharm 28:1-13. 2002
    ..NP technology appears to have significant promise in delivering therapeutic molecules across the BBB...
  24. ncbi Drug development for CNS disorders: strategies for balancing risk and reducing attrition
    Menelas N Pangalos
    Wyeth Research, Neuroscience Discovery, CN800, Princeton, New Jersey 08543, USA
    Nat Rev Drug Discov 6:521-32. 2007
    ....
  25. ncbi Prodrugs of thyrotropin-releasing hormone and related peptides as central nervous system agents
    Katalin Prokai-Tatrai
    Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA
    Molecules 14:633-54. 2009
    ..The value of prodrug-amenable analogues as potential drug-like central nervous systems agents was highlighted...
  26. pmc Translational research in central nervous system drug discovery
    Orest Hurko
    Translational Research, Wyeth, Collegeville, Pennsylvania 19426, USA
    NeuroRx 2:671-82. 2005
    ..Implementation of new technologies is the key to success in this emerging endeavor...
  27. ncbi [Physiological function of blood-brain barrier transporters as the CNS supporting and protecting system]
    Sumio Ohtsuki
    Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba ku, Sendai 980 8578, Japan
    Yakugaku Zasshi 124:791-802. 2004
    ....
  28. ncbi Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 2. Cationic peptide vectors for brain delivery
    M Adenot
    Synt em, Nimes, Paris, France
    Chemotherapy 53:73-6. 2007
    ..Based on both in vivo and in vitro experimental data, a cell uptake component has been added to our computational model of blood-brain barrier...
  29. ncbi Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 1. Anti-infective drugs
    M Adenot
    Synt em, Nimes, Paris, France
    Chemotherapy 53:70-2. 2007
    ..High Pe score values are associated with an increase of reported CNS side effects...
  30. ncbi Death-associated protein kinase as a potential therapeutic target
    Andrew M Schumacher
    Drug Discovery Programme, Department of Molecular Pharmacology and Biological Chemistry, 303 East Chicago Avenue, Ward 8 196, Chicago, IL 60611, USA
    Expert Opin Ther Targets 6:497-506. 2002
    ..This article provides a brief summary of relevant research and the rationale that is at the foundation of this opinion...
  31. ncbi Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development
    Sumio Ohtsuki
    Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba, Aramaki, Aoba ku, Sendai, 980 8578, Japan
    Pharm Res 24:1745-58. 2007
    ..Proteomic studies may also provide important insights into human BBB function. Construction of a human BBB transporter atlas would be a most important advance from the viewpoint of CNS drug discovery and drug delivery to the brain...
  32. ncbi Progress in brain penetration evaluation in drug discovery and development
    Xingrong Liu
    Roche Palo Alto, 3431 Hillview Avenue S3 2, Palo Alto, CA 94304, USA
    J Pharmacol Exp Ther 325:349-56. 2008
    ..2) Selection of P-gp substrates as drug candidates for non-CNS targets can reduce their CNS-mediated side effects...
  33. ncbi 4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention
    Marlon Cowart
    Department of Neuroscience Research, Abbott Laboratories, Abbott Park, Illinois 60064 6123, USA
    J Med Chem 48:38-55. 2005
    ..The potency and selectivity of this compound and of analogues from this class support the potential of H(3) receptor antagonists for the treatment of cognitive dysfunction...
  34. ncbi Donepezil, tacrine and alpha-phenyl-n-tert-butyl nitrone (PBN) inhibit choline transport by conditionally immortalized rat brain capillary endothelial cell lines (TR-BBB)
    Young Sook Kang
    College of Pharmacy, Sookmyung Women s University, Seoul, Korea
    Arch Pharm Res 28:443-50. 2005
    ..Accordingly, these results suggest that OCT2 is a candidate for choline transport at the BBB and may influence the BBB permeability of amine drugs...
  35. ncbi Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction
    Scott G Summerfield
    Department of Drug Metabolism and Pharmacokinetics, Neurology and Gastrointestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline R and D, New Frontiers Science Park, Third Ave, Harlow, Essex CM19 5AW, UK
    J Pharmacol Exp Ther 322:205-13. 2007
    ..These findings corroborate recent reports in the literature that brain penetration is a function of both rate and extent of drug uptake into the CNS...
  36. ncbi New aspects of the blood-brain barrier transporters; its physiological roles in the central nervous system
    Sumio Ohtsuki
    Department of Molecular Biopharmacy and Genetics, Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba ku, Sendai, Japan
    Biol Pharm Bull 27:1489-96. 2004
    ..Clarifying the physiological roles of BBB transport systems should give us important information allowing the development of better CNS drugs and improving our understanding of the relationship between CNS disorders and BBB function...
  37. ncbi Expression and function of cytochrome p450 in brain drug metabolism
    R P Meyer
    Pathologisches Institut, Abt Neuropathologie, Neurozentrum, Universitatsklinik Freiburg, Breisacher Strasse 64, D 79106 Freiburg, Germany
    Curr Drug Metab 8:297-306. 2007
    ..The understanding of brain P450 function appears to be of major interest in long-term drug mediated therapy of neurological diseases...
  38. ncbi Neuropharmacological evaluation of Ginkgo biloba phytosomes in rodents
    Suresh R Naik
    Department of Pharmacology and Toxicology, Principal K M Kundnani College of Pharmacy, Jote Joy Building, Rambhau Salgaonkar Marg, Cuffe Parade, Colaba, Mumbai 400 005, India
    Phytother Res 20:901-5. 2006
    ..However, the phytosomes failed to show anticonvulsant activity. The observations suggest that the G. biloba phytosomes possess moderate antiamnestic/nootropic activity...
  39. ncbi The influence of some aminoalkanolic xanthone derivatives on central nervous and cardiovascular systems in rodents
    Tadeusz Librowski
    Department of Pharmacodynamics, Faculty of Pharmacy, Medical College, Jagiellonian University, Krakow, Poland
    Boll Chim Farm 143:267-74. 2004
    ....
  40. ncbi Correlation of blood-brain penetration using structural descriptors
    Alan R Katritzky
    Center for Heterocyclic Compounds, Department of Chemistry, University of Florida, Gainesville, FL 32611, USA
    Bioorg Med Chem 14:4888-917. 2006
    ..781 and standard deviation s2=0.123. The 'consensus model' of ISIDA gave R2=0.872 and s2=0.047. The developed models were successfully validated using the central nervous system activity data of an external test set of 40 drug molecules...
  41. pmc The blood-brain barrier: bottleneck in brain drug development
    William M Pardridge
    Department of Medicine, UCLA, Los Angeles, California 90024, USA
    NeuroRx 2:3-14. 2005
    ..This provides the platform for CNS drug delivery programs, which should be developed in parallel with traditional CNS drug discovery efforts in the molecular neurosciences...
  42. ncbi Design and synthesis of a maximally diverse and druglike screening library using REM resin methodology
    D Barn
    Lead Discovery Chemistry, Organon Laboratories Ltd, Newhouse, ML1 5SH, Scotland
    J Comb Chem 3:534-41. 2001
    ..Encouragingly, hits have been identified from high-throughput screening of this library, such as compound 6, which has an affinity of 1.02 microM for the GlyT(2) transporter...
  43. pmc Membrane transporter proteins: a challenge for CNS drug development
    François Girardin
    Unit of Clinical Psychopharmacology, Geneva University Hospitals, Chênes Bourg, Geneva, Switzerland
    Dialogues Clin Neurosci 8:311-21. 2006
    ..They are ATP-independent polypeptides principally expressed at the basolateral membrane of brain capillary and choroid plexus endothelial cells that also mediate drug transport through central nervous system barriers...
  44. ncbi Prediction of CNS activity of compound libraries using substructure analysis
    Ola Engkvist
    CallistoGen AG, Neuendorfstrasse 24b, D 16761 Hennigsdorf, Germany
    J Chem Inf Comput Sci 43:155-60. 2003
    ..SUBSTRUCT separates the data sets with approximately 80% accuracy. Substructural analysis also shows surprisingly large differences in substructure profiles between CNS active and nonactive drugs...
  45. ncbi Nanobiotechnology-based drug delivery to the central nervous system
    K K Jain
    Jain PharmaBiotech, Basel, Switzerland
    Neurodegener Dis 4:287-91. 2007
    ..Drug delivery across the blood-brain barrier (BBB) is a major limitation in the treatment of central nervous system (CNS) disorders. Several approaches are being investigated to improve drug delivery across the BBB...
  46. ncbi Blood-brain barrier permeation models: discriminating between potential CNS and non-CNS drugs including P-glycoprotein substrates
    Marc Adenot
    Synt em, Parc Scientifique G Besse, 30000 Nimes, France
    J Chem Inf Comput Sci 44:239-48. 2004
    ..Moreover, a "CNS drugs" map, including P-gp substrates and accurately reflecting the in vivo behavior of drugs, is proposed as a tool for CNS drug virtual screening...
  47. ncbi A role for fMRI in optimizing CNS drug development
    David Borsook
    Imaging Center for Drug Development ICD, McLean Hospital, Department of Psychiatry, USA
    Nat Rev Drug Discov 5:411-24. 2006
    ..fMRI can help optimize CNS drug discovery by providing a key metric that can increase confidence in early decision-making, thereby improving success rates and reducing risk, development times and costs of drug development...
  48. ncbi Novel G-protein-coupled receptor genes expressed in the brain: continued discovery of important therapeutic targets
    Dennis K Lee
    Department of Pharmacology, University of Toronto, Medical Science Building, 8 Taddle Creek Rd Rm 4352, Toronto, Ontario M5S 1A8, Canada
    Expert Opin Ther Targets 6:185-202. 2002
    ..Equipped with proven ligand identification strategies, the characterisation of all orphan GPCRs and the exploitation of their exciting potential as targets for the discovery of novel drugs is anticipated...
  49. ncbi Pharmacokinetics of Gastrodin in rat plasma and CSF after i.n. and i.v
    Qiao Wang
    Department of Pharmaceutical Analysis and Drug Metabolism, College of Pharmaceutical Sciences, Zi Jin Gang Campus, Zhejiang University, Hangzhou, Zhejiang 310058, PR China
    Int J Pharm 341:20-5. 2007
    ..The drug targeting index (DTI) was 12.34. In conclusion, intranasal administration of Gastrodin is a promising alternative to traditional administration. Olfactory mucosa did present another pathway for transport Gastrodin to the brain...
  50. ncbi Endocytosis at the blood-brain barrier: from basic understanding to drug delivery strategies
    Mathew W Smith
    Pharmaceutical Cell Biology, Welsh School of Pharmacy, Cardiff University, Redwood Building, Cardiff CF10 3XF, UK
    J Drug Target 14:191-214. 2006
    ....
  51. pmc Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy
    David S Miller
    Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA
    Pharmacol Rev 60:196-209. 2008
    ..Finally, several steps in signaling are potential therapeutic targets that could be used to modulate P-glycoprotein activity in the clinic...
  52. ncbi Drug delivery to brain by microparticulate systems
    H Suheyla Kas
    Department of Pharmaceutical Technology, University of Hacettepe, Sihhiye, Ankara, Turkey
    Adv Exp Med Biol 553:221-30. 2004
    ..1). The purpose of this paper is to summarise the methods for BBB permeability modifications and to focus on various examples in delivering drugs, especially neuroncology and neuroactive drugs, to brain by microparticulate systems...
  53. ncbi Cerebral uptake of drugs in humans
    Richard N Upton
    Department of Anaesthesia and Intensive Care, Royal Adelaide Hospital, Adelaide, South Australia, Australia
    Clin Exp Pharmacol Physiol 34:695-701. 2007
    ..6. Continuing to exploit and develop these methods may provide new avenues to enhance the safety and efficacy of cerebro-active drugs in clinical practice...
  54. ncbi The blood-brain barrier choline transporter as a brain drug delivery vector
    D D Allen
    Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, 79106 1712, USA
    Life Sci 73:1609-15. 2003
    ..Future work is being completed to determine if other cationic or positively charged therapeutics can be effectively delivered to brain via this carrier...
  55. ncbi [Breaking down barriers--about the art of escorting drugs into the brain]
    Ulrika Kahl
    Lakartidningen 100:136-7. 2003
  56. ncbi Structure-activity relationships and effects on neuroactive steroid synthesis in a series of 2-phenylimidazo[1,2-a]pyridineacetamide peripheral benzodiazepine receptors ligands
    Giuseppe Trapani
    Dipartimento Farmaco Chimico, Facolta di Farmacia, Universita degli Studi di Bari, Via Orabona 4, 70125 Bari, Italy
    J Med Chem 48:292-305. 2005
    ..Compound 3 exhibited very marked effects on the peripheral and central synthesis of neuroactive steroids, while 36 (potent at subnanomolar level) showed a slight ability to affect neuroactive steroid content in the cerebral cortex...
  57. ncbi The role of molecular imaging in drug discovery and development
    R J Hargreaves
    Imaging and Proteomics, Merck Research Laboratories, Merck and Co Inc, West Point, Pennsylvania, USA
    Clin Pharmacol Ther 83:349-53. 2008
    ..Molecular imaging can be used to improve the cost-effectiveness of studying unprecedented mechanisms, decrease cycle time, and improve drug pipeline quality...
  58. ncbi Validation of a motor activity system by a robotically controlled vehicle and using standard reference compounds
    John P Patterson
    Investigational and Regulatory Safety Pharmacology, Schering Plough Research Institute, Lafayette, NJ 07848, USA
    J Pharmacol Toxicol Methods 52:159-67. 2005
    ..4.01, Hamilton-Kinder, LLC, for use in a good laboratory practices (GLP) Safety Pharmacology laboratory...
  59. ncbi Spectrum of effects detected in the rat functional observational battery following oral administration of non-CNS targeted compounds
    William S Redfern
    Safety Assessment UK, AstraZeneca R and D Alderley Park, Cheshire SK10 4TG, UK
    J Pharmacol Toxicol Methods 52:77-82. 2005
    ....
  60. ncbi Region-specific effects of brain corticotropin-releasing factor receptor type 1 blockade on footshock-stress- or drug-priming-induced reinstatement of morphine conditioned place preference in rats
    Jishi Wang
    Department of Pharmacology, The Affiliated Hospital of Guiyang Medical College, Guiyang 550004, China
    Psychopharmacology (Berl) 185:19-28. 2006
    ..However, the brain sites involved in the effect of CP-154,526 on footshock-induced reinstatement of opiate seeking are unknown...
  61. ncbi Sensorimotor deficits and increased brain nicotinic acetylcholine receptors following exposure to chlorpyrifos and/or nicotine in rats
    Mohamed B Abou-Donia
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
    Arch Toxicol 77:452-8. 2003
    ..These data suggest that exposure to either nicotine or chlorpyrifos or a combination of the two may impair neurobehavioral performance and affect the central nervous system cholinergic pathways...
  62. ncbi Changes of [3H]MK-801, [3H]muscimol and [3H]flunitrazepam binding in rat brain by the prolonged ventricular infusion of transformed ginsenosides
    Soyong Jang
    Department of Neuroscience, College of Medicine, Ewha University, Seoul, Korea
    Neurochem Res 29:2257-66. 2004
    ..These results suggest that biotransformed ginsenoside Rh2 and compound K could play an important role in the biological activities in the central nervous systems and neurodegenerative disease...
  63. ncbi A systematic review of currently available pharmacological neuroprotective agents as a sole intervention before anticipated or induced cardiac arrest
    Manuela Weigl
    Department of Anaesthesiology and General Intensive Care, Division of Cardiothoracic and Vascular Anaesthesia and Intensive Care, University Hospital Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Resuscitation 65:21-39. 2005
    ....
  64. ncbi A pyridinium-substituted analog of the TRH-like tripeptide pGlu-Glu-Pro-NH2 and its prodrugs as central nervous system agents
    K Prokai-Tatrai
    Department of Medicinal Chemistry, College of Pharmacy, University of Florida, 1600 Archer Road, Gainesville, FL 32610 0485, USA
    Med Chem 1:141-52. 2005
    ..The novel analog maintained its antidepressant potency but showed reduced analeptic action compared to [Glu2]TRH; thus, an increase in the selectivity of CNS-action was obtained by the incorporation of the pyridinium moiety...
  65. ncbi Positron emission tomography in central nervous system drug discovery and development
    Malcolm Cooper
    Department of Radiology, University of Chicago, 2843 West Rascher, Chicago, IL 60625, USA
    Neuroimaging Clin N Am 13:851-6, xi. 2003
    ..One particular approach, built around [18F]fluordeoxyglucose positron emission tomography, is described...
  66. pmc Central nervous system drug development: an integrative biomarker approach toward individualized medicine
    B Gomez-Mancilla
    Neuroscience Biomarker Development, Novartis Pharma, CH 4002 Basel, Switzerland
    NeuroRx 2:683-95. 2005
    ..The present review represent an effort to illustrate the integration of such technologies in drug development supporting the path of individualized medicine...
  67. pmc Antibody-based validation of CNS ion channel drug targets
    Kenneth J Rhodes
    Discovery Neurobiology, Biogen Idec, Cambridge, MA 02142, USA
    J Gen Physiol 131:407-13. 2008
  68. ncbi [Pharmacological effects of volatile oil of Valeriana amurensis on CNS]
    Jun kai Wu
    Pharmaceutical College, Heilongjiang University of Chinese Medicine, Harbin 150040, China
    Zhong Yao Cai 30:977-80. 2007
    ..To study the pharmacological effects of volatile oil of Valeriana amurensis on central nervous system...
  69. ncbi [Development of new drugs targeting glial cells]
    Yoshihisa Kudo
    Nihon Yakurigaku Zasshi 130:185-92. 2007
  70. ncbi Further characterization of high mobility group box 1 (HMGB1) as a proinflammatory cytokine: central nervous system effects
    Kevin A O'Connor
    Department of Psychology and Center for Neuroscience, University of Colorado, Boulder, CO 80309, USA
    Cytokine 24:254-65. 2003
    ..Nonetheless, these data suggest that HMGB1 may play a role as an endogenous pyrogen and support the concept that HMGB1 has proinflammatory characteristics within the central nervous system...
  71. ncbi [Central nervous system diseases induced by drug therapies]
    Masahiro Nomoto
    Nihon Naika Gakkai Zasshi 96:1580-4. 2007
  72. ncbi Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression
    Paul R Gard
    University of Brighton, School of Pharmacy and Biomolecular Sciences, UK
    Expert Opin Ther Targets 8:7-14. 2004
    ..Such effects, if proven, could promote the use of such agents in the treatment of hypertension coexisting with depression or anxiety...
  73. ncbi Polymeric nanoparticles for the drug delivery to the central nervous system
    Giovanni Tosi
    University of Modena and Reggio Emilia, Department of Pharmaceutical Sciences, Italy
    Expert Opin Drug Deliv 5:155-74. 2008
    ..This approach has been recently considered for the therapy of brain diseases. The major problem in accessing the CNS is linked to the presence of the blood-brain barrier...
  74. ncbi Reading and writing the blood-brain barrier: relevance to therapeutics
    Barry M Czeisler
    Case Western Reserve University School of Medicine, Cleveland, OH, USA
    Recent Pat CNS Drug Discov 1:157-73. 2006
    ..These techniques for both "reading" and "writing" the BBB will help new and old medications to reach their pharmacological targets in the CNS...
  75. ncbi Types of medication errors in North Carolina nursing homes: a target for quality improvement
    Richard A Hansen
    Division of Pharmaceutical Outcomes and Policy, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Am J Geriatr Pharmacother 4:52-61. 2006
    ..Gaining a better understanding of the types of medications commonly involved in medication errors in nursing homes would be an important step toward quality improvement...
  76. ncbi Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain
    Philip H Elsinga
    PET Center, Groningen University Hospital, Groningen, The Netherlands
    Mol Imaging Biol 7:37-44. 2005
    ..0 after full modulation with CsA. By quantitative PET measurement of P-gp function, the dose of modulators required to increase the concentration of CNS drugs may be determined, which may result in improved drug therapy...
  77. ncbi Clinical drugs that interact with St. John's wort and implication in drug development
    Yuan Ming Di
    Divison of Chinese Medicine, School of Health Sciences, RMIT University, Bundoora, Victoria 3083, Australia
    Curr Pharm Des 14:1723-42. 2008
    ..g. digoxin, ivabradine, warfarin, verapamil, nifedipine and talinolol), central nervous system agents (e.g...
  78. ncbi Unfilled prescriptions of medicare beneficiaries: prevalence, reasons, and types of medicines prescribed
    Jae Kennedy
    Department of Health Policy and Administration, College of Pharmacy, Washington State University, PO Box 1495, Spokane, WA, 99210 1495, USA
    J Manag Care Pharm 14:553-60. 2008
    ..Medicare beneficiaries have high rates of chronic illness and prescription medication use, making this population particularly vulnerable to nonadherence. Failure to fill prescribed medication is a key component of nonadherence...
  79. ncbi Current and investigational antiobesity agents and obesity therapeutic treatment targets
    Harold E Bays
    FACP Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Ave, Louisville, KY 40213, USA
    Obes Res 12:1197-211. 2004
    ..Investigational antiobesity agents consist of 1) central nervous system agents that affect neurotransmitters or neural ion channels, including antidepressants (bupropion), selective ..
  80. ncbi Transcranial magnetic stimulation: applications for neuropsychopharmacology
    Seppo Kahkonen
    BioMag Laboratory, Engineering Centre, Helsinki University Central Hospital and Cognitive Brain Research Unit, Department of Psychology, University of Helsinki, Helsinki, Finland
    J Psychopharmacol 18:257-61. 2004
    ..Taken together, TMS provides a new insight to the actions of central nervous system drugs at the cortical level...
  81. ncbi Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data
    J Cory Kalvass
    School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    J Pharmacol Exp Ther 323:346-55. 2007
    ....
  82. pmc Transcranial route of brain targeted delivery of methadone in oil
    W Pathirana
    Department of Pharmacology and Pharmacy, Faculty of Medicine, University of Colombo, Kynsey Road, Colombo 8, Sri Lanka
    Indian J Pharm Sci 71:264-9. 2009
    ..Therefore, it is possible to deliver central nervous system drugs through the proposed transcranial route when suitably formulated...
  83. ncbi An economic assessment of the extent of medication use and wastage among families in Saudi Arabia and Arabian Gulf countries
    Hisham S Abou-Auda
    College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
    Clin Ther 25:1276-92. 2003
    ..To this end, medication wastage is an unnecessary burden on an already fiscally restrained health care system...
  84. ncbi Functional expression of taurine transporter and its up-regulation in developing neurons from mouse cerebral cortex
    Takuya Fujita
    Department of Biochemical Pharmacology, Kyoto Pharmaceutical University, Misasagi, Yamashina ku, Kyoto, 607 8414, Japan
    Pharm Res 23:689-96. 2006
    ..In the present study, we investigate the characteristics of taurine transport in primary cultures of neurons from mouse cerebral cortex to understand the possibility that taurine might attenuate the effects of central nervous system drugs...
  85. ncbi Pattern of acute food, drug, and chemical poisoning in Sari City, Northern Iran
    Amirhossein Ahmadi
    Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
    Hum Exp Toxicol 29:731-8. 2010
    ..Establishing poison information centers in different parts of the country, preparing national treatment guidelines, training healthcare providers, and ensuring easy availability of the antidotes are also recommended...
  86. ncbi Medication errors recovered by emergency department pharmacists
    Jeffrey M Rothschild
    Division of General Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Ann Emerg Med 55:513-21. 2010
    ..We assess the impact of emergency department (ED) pharmacists on reducing potentially harmful medication errors...
  87. ncbi Brain uptake of ketoprofen-lysine prodrug in rats
    Mikko Gynther
    School of Pharmacy, University of Eastern Finland, Kuopio, Finland
    Int J Pharm 399:121-8. 2010
    ..In addition, our results show that although lysine or ketoprofen are not LAT1-substrates themselves, by combining these molecules, the formed prodrug has affinity for LAT1...
  88. ncbi A survey on the extent of medication storage and wastage in urban Iranian households
    A H Zargarzadeh
    Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Iran
    Clin Ther 27:970-8. 2005
    ..The limited resources of developing countries warrant more careful assessments of current national drug policies...
  89. ncbi Potential risks and prevention, Part 1: Fatal adverse drug events
    W N Kelly
    Department of Pharmacy Administration, Southern School of Pharmacy, Mercer University, 3001 Mercer University Drive, Atlanta, GA 30341 4155, USA
    Am J Health Syst Pharm 58:1317-24. 2001
    ..1 million. A review of published case reports of ADEs for 1976-95 yielded information on possible risk factors for fatal ADEs and on which events may have been preventable...
  90. ncbi Pattern of drug prescription and utilization among Bam residents during the first six months after the 2003 Bam earthquake
    Gholamreza Sepehri
    Physiology and Pharmacology Department, Neuroscience Research Center, Kerman University of Medical Sciences, Kerman, Iran
    Prehosp Disaster Med 21:396-402. 2006
    ..3 on the Richter scale struck southeastern Iran, decimating the city of Bam. In this study, the most frequently utilized and prescribed drugs for Bam outpatients during the first six months after the Bam Earthquake were investigated...
  91. ncbi Drug utilization and potentially inappropriate drug use in elderly residents of a community in Istanbul, Turkey
    P Ay
    Department of Public Health, School of Medicine, Marmara University, Istanbul, Turkey
    Int J Clin Pharmacol Ther 43:195-202. 2005
    ..This study investigates drug utilization and estimates the prevalence of potentially inappropriate drug use in a Turkish population aged 70 years or older...
  92. ncbi Drug consumption among Polish centenarians
    A Rajska-Neumann
    Department of Geriatrics and Gerontology, University of Medical Science, 6 Swiecickiego Street, 60 681 Poznan, Poland
    Arch Gerontol Geriatr 53:e29-32. 2011
    ..To conclude, the mean number of drugs, the prevalence of polypharmacy, and the tendency for potential inappropriateness of treatment are lower among Polish centenarians comparing to the common elderly...
  93. ncbi Influence of lipophilicity on the interactions of N-alkyl-4-phenyl-1,2,3,6-tetrahydropyridines and their positively charged N-alkyl-4-phenylpyridinium metabolites with cytochrome P450 2D6
    Amit S Kalgutkar
    Pharmacokinetics, Dynamics, and Metabolism Department, Pfizer Global Research and Development, Groton, Connecticut 06340, USA
    Drug Metab Dispos 31:596-605. 2003
    ..This phenomenon appears to be a common theme among several cyclic tertiary amine-containing anti-depressants and should be taken into consideration when designing central nervous system agents devoid of CYP2D6 substrate properties.
  94. ncbi Inappropriate medication prescribing for elderly ambulatory care patients
    Margie Rauch Goulding
    Office of Analysis, Epidemiology, and Health Promotion at the National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, MD 20782, USA
    Arch Intern Med 164:305-12. 2004
    ..Inappropriate medication use in elderly patients has been linked to a large share of adverse drug reactions and to excess health care utilization...
  95. ncbi Tenfold medication dose prescribing errors
    Timothy S Lesar
    Albany Medical Center, Mail code 85, 43 New Scotland Ave, Albany, New York 12208 3412, USA
    Ann Pharmacother 36:1833-9. 2002
    ..Few systematic evaluations of the characteristics and causes of tenfold medication dosage prescribing errors have been performed...
  96. ncbi Use of PET and the radioligand [carbonyl-(11)C]WAY-100635 in psychotropic drug development
    B Andree
    Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Stockholm, Sweden
    Nucl Med Biol 27:515-21. 2000
    ..These studies reviewed here illustrate and corroborate that quantitative neuroimaging of receptor binding has potential for the evaluation and dose finding of new central nervous system drugs...
  97. ncbi Discontinuation and reinstitution of medications during the perioperative period
    Steven E Pass
    Department of Pharmacy Services, University Hospital, Cincinnati, OH 45219 2316, USA
    Am J Health Syst Pharm 61:899-912; quiz 913-4. 2004
    ..the discontinuation and reinstitution of long-term therapies, including cardiovascular agents, anticoagulants and antiplatelet agents, central nervous system agents, and herbal medicines, in the perioperative period are discussed.
  98. ncbi Potential risks and prevention, Part 4: Reports of significant adverse drug events
    W N Kelly
    Department of Pharmacy Administration, Southern School of Pharmacy, Mercer University, 3001 Mercer University Drive, Atlanta, GA, USA
    Am J Health Syst Pharm 58:1406-12. 2001
    ..1 million. A summary analysis of more than 1500 published case reports of ADEs for 1976-97 yielded information on possible risk factors for drug-related deaths, disabilities, and life threats and on which events may have been preventable...
  99. ncbi Pharmacogenomics of antipsychotics efficacy for schizophrenia
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, Bergondo, Coruna, Spain
    Psychiatry Clin Neurosci 65:3-19. 2011
    ....
  100. ncbi Immortalized human brain endothelial cells and flow-based vascular modeling: a marriage of convenience for rational neurovascular studies
    Luca Cucullo
    Division of Cerebrovascular Research, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio 44195, USA
    J Cereb Blood Flow Metab 28:312-28. 2008
    ..Pretreatment with ibuprofen (0.125 mmol/L) prevented BBB failure by decreasing the inflammatory response after flow cessation/reperfusion...
  101. ncbi Examination of multiple medication use among TRICARE beneficiaries aged 65 years and older
    Andrea Linton
    OASD HA, 5111 Leesburg Pike, Suite 810, Falls Church, VA 22041 3206, USA
    J Manag Care Pharm 13:155-62. 2007
    ..The simultaneous use of multiple prescription medications has been associated with an increased risk of adverse drug events and other drug-related complications, especially in the elderly...

Research Grants66

  1. Neurotrophin Blood/Brain Barrier Delivery in Ischemia
    William Pardridge; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  2. PTS1 Regulation of Brain Met Enk Levels in Alcoholism
    William Banks; Fiscal Year: 2004
    ..abstract_text> ..
  3. BLOOD BRAIN BARRIER LARGE NEUTRAL AMINO ACID TRANSPORTER
    William Pardridge; Fiscal Year: 2003
    ..These studies will provide new molecular biological information on a crucial transporter at the blood-brain barrier that regulates the supply in the brain of essential amino acids. ..
  4. Multiplexed flow cytometry screens for RGS inhibitors
    Richard Neubig; Fiscal Year: 2007
    ..The ultimate aim of this project is the identification of selective small molecule inhibitors of RGS action. This will provide important chemical tools and accelerate the development of novel therapeutics. ..
  5. AMPHETAMINE ENHANCED STROKE RECOVERY--BURKE SRCI GROUP
    Larry Goldstein; Fiscal Year: 2002
    ..However the treatment duration will be increased to a total of 10 sessions. ..
  6. STRUCTURAL BASIS OF RECEPTOR/G PROTEIN FUNCTION
    Richard Neubig; Fiscal Year: 2004
    ..This work should greatly improve our understanding of the structural and mechanistic basis of RG coupling and should facilitate the design of drugs that target particular G protein subunit combinations. ..
  7. Prion Transport Across the Blood-Brain Barrier
    William Banks; Fiscal Year: 2009
    ..To cause disease, prions must cross the blood-brain barrier to enter the brain. We will determine how prions cross the BBB. Knowing how prions enter the brain should lead to strategies on how to prevent prion diseases. ..
  8. Mechanisms of HIV Transport Across the BBB
    William Banks; Fiscal Year: 2004
    ....
  9. AIDS Neurotherapeutics and BBB Drug Efflux
    William Pardridge; Fiscal Year: 2007
    ..This work provides the basis for future drug discovery of AET blockers, which can be used as co-drugs to increase CNS penetration of HAART drugs. ..
  10. REGULATION OF BBB GLUT1 GLUCOSE TRANSPORTER
    William Pardridge; Fiscal Year: 2002
    ..These studies will provide insight into molecular mechanisms of regulation of a step crucial to the maintenance of cerebral intermediary metabolism, i.e., the continuous transport of glucose across the blood-brain barrier in vivo. ..
  11. MIDCAREER INVESTIGATOR AWARD IN CEREBROVASCULAR RESEARCH
    Larry Goldstein; Fiscal Year: 2004
    ....
  12. Antisense imaging of brain gene expression in vivo
    William Pardridge; Fiscal Year: 2005
    ..This technology could be extended to humans and to other organs. At present, there is no parallel technology that enables the non-invasive in vivo imaging of "any gene in any person," which is the goal of this work. ..
  13. Non-Viral Gene Targeting to the Brain
    William Pardridge; Fiscal Year: 2008
    ..abstract_text> ..
  14. Opiate Addiction and HIV-1 Induced Release of Cytokines
    William Banks; Fiscal Year: 2006
    ....
  15. Angiogenic determinants of endogenous adult neurogenesis
    Steven Goldman; Fiscal Year: 2008
    ....
  16. mGluR4 Potentiators as a Treatment for Parkinson's Disease
    P Conn; Fiscal Year: 2007
    ..This high throughput screen will provide the basis for future studies aimed at developing allosteric potentiators of mGluR4 that are suitable for clinical testing. [unreadable] [unreadable]..
  17. DELIRIUM IN PERSONS WITH DEMENTIA
    Donna Fick; Fiscal Year: 2007
    ..Ultimately, the results from this and subsequent studies should improve the lives of persons with dementia and their caregivers by decreasing delirium-related complications and hospitalizations. [unreadable] [unreadable] [unreadable]..
  18. High End Computing for PET/SPECT
    DEAN WONG; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  19. Functional effects of mGluR potentiators in the CNS
    P Jeffrey Conn; Fiscal Year: 2010
    ....
  20. Protective Influence of Residential Learning Communities
    SEAN MCCABE; Fiscal Year: 2006
    ..At each measurement point, participants will complete a set of measures that assess substance use behaviors and constructs addressed by RLCs. ..
  21. Nursing Home IT: Optimal Medication and Care Delivery
    Susan Horn; Fiscal Year: 2006
    ..Distill and summarize lessons learned about what is critical for successful implementation of HIT in nursing homes, including facilitators, barriers, and strategies to address them. ..
  22. Novel Glutamatergic Detoxification Strategies
    John Krystal; Fiscal Year: 2006
    ..abstract_text> ..
  23. Induction of Striatal Regeneration in Huntington's Disease
    Steven Goldman; Fiscal Year: 2009
    ....
  24. Sites and Mechanisms of Ethanol Action in P2X receptors
    DARYL DAVIES; Fiscal Year: 2009
    ....
  25. Blood Brain Barrier Physiology and HIV Dementia
    HOWARD GENDELMAN; Fiscal Year: 2007
    ..The data acquired could provide new insights and therapeutic intervention strategies for monocyte BBB trafficking during progressive HIV-1 infection in brain tissue. ..
  26. DIETARY OBESITY
    George Bray; Fiscal Year: 2007
    ..We now propose these well founded, important and exciting studies which will provide critical new insights into anatomical, physiological and molecular mechanisms by which high levels of dietary fat induce obesity. ..
  27. AMINO ACID NEUROTRANSMITTER DYSREGULATION IN ALCOHOLISM
    John Krystal; Fiscal Year: 2008
    ..abstract_text> ..
  28. Regulation of Hypothalamic Sleep-wake Neuronal System
    NOOR ALAM; Fiscal Year: 2008
    ..This will contribute to the search for more targeted and specific therapeutic strategies for sleep disorders. ..
  29. Estrogens for Alcoholism & Its Neurological Consequences
    James Simpkins; Fiscal Year: 2008
    ..the proposed studies will provide new knowledge on the mechanism of estrogen protection from the consequences of EW and determine if estrogens are potential pharmacotherapies for alcoholism and its consequences [unreadable] [unreadable]..
  30. Topiramate for alcohol and cocaine dependence
    Kyle Kampman; Fiscal Year: 2008
    ..abstract_text> ..
  31. Sexual Orientation, Substance Use and Mental Health
    SEAN MCCABE; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  32. A High Throughput Screen for Inhibitors of a Novel Necrotic Cell Death Pathway
    Junying Yuan; Fiscal Year: 2007
    ..Necroptosis has been shown to be a promising target for the treatment of stroke as it represents a type of delayed cell death in stroke and offers an extended time window for therapy. [unreadable] [unreadable] [unreadable]..
  33. The Amygdala, Individual Differences, and Conditioned Hyperactivity
    Mary Cain; Fiscal Year: 2007
    ..The findings of these experiments are intended to advance the understanding of vulnerability for stimulant abuse, and will potentially lead to better prevention and treatment interventions. [unreadable] [unreadable] [unreadable]..
  34. 2008 AUA/SBUR Summer Research Conference
    Arthur Burnett; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  35. Validation of the NINDS VCI Neuropsychology Protocols
    David Nyenhuis; Fiscal Year: 2009
    ..Reliable and valid VCI neuropsychology test protocols are a necessary first step to improved diagnostic criteria and a better understanding of both the mechanisms of VCI and the development of new treatment options. ..
  36. Life Cycle Effects of Health Insurance on Elderly Health
    Jalpa Doshi; Fiscal Year: 2006
    ..We will use these estimates to simulate the effect of changes in the age of Medicare eligibility on health, medical service use and Medicare expenditure. ..
  37. Genetics of Attention Deficit-Hyperactivity Disorder
    James Swanson; Fiscal Year: 2006
    ..Genomic haplotypes", meaning haplo-specific genotypes at more than one locus, will be defined and tested for possible interactive roles among the genes. ..
  38. CONTROL OF SLEEP AND AROUSAL
    NOOR ALAM; Fiscal Year: 2003
    ..These pharmacological manipulations and analytical procedures will help understanding of the adenosinergic and GABAergic mechanisms that shape the discharge patterns of the MBF neurons across the sleep-waking cycle. ..
  39. AMINO ACID NEUROTRANSMITTER DYSREGULATION IN ALCOHOLISM
    John Krystal; Fiscal Year: 2003
    ..In summary, this K02 award would foster my academic development and enable me to better contribute to the building of pathophysiologic models of alcoholism that can guide medications development for this disorder. ..
  40. Symposium on Neuroimaging in Alcoholism
    John Krystal; Fiscal Year: 2003
    ..A call for abstracts also will bring forward names and ideas from other groups that might be added to the main program. Young Investigator travel scholarships will be considered. ..
  41. UCI-CFC Projects on School Readiness
    James Swanson; Fiscal Year: 2002
    ....
  42. BEHAVIORAL EFFECTS OF NIGRAL D1 ANTAGONISM
    John Salamone; Fiscal Year: 2001
    ....
  43. BASAL GANGLIA FMRI IN NORMAL AND PARKINSONIAN PATIENTS
    Alice Flaherty; Fiscal Year: 2002
    ..abstract_text> ..
  44. TREATMENT FOR ALCHOLISM: A PRIMATE MODEL
    KELLY COSGROVE; Fiscal Year: 2002
    ..Thus, the effects of bremazocine and naltrexone on ethanol self-administration as a function of sex will be investigated. ..
  45. CHOLINERGIC AND OPIATE MECHANISMS IN DRUG REINFORCEMENT
    Shafiqur Rahman; Fiscal Year: 2002
    ....
  46. NEURONAL ELECTROPHYSIOLOGY IN HIV DEMENTIA
    HOWARD GENDELMAN; Fiscal Year: 2001
    ....
  47. IMAGING DOPAMINE/SEROTONIN MECHANISMS IN COCAINE CRAVING
    DEAN WONG; Fiscal Year: 2003
    ..Testing of these hypotheses will provide novel and fundamental answers to craving mechanisms. ..
  48. MECHANISM & FUNCTIONS OF ICH-3 IN APOPTOSIS/INFLAMMATION
    Junying Yuan; Fiscal Year: 2001
    ..These works will have direct implication in control of apoptosis in normal and inflammatory conditions. ..
  49. The Amygdala and Amphetamine Self-Administration
    Mary Cain; Fiscal Year: 2003
    ..The findings from these experiments are intended to advance the understanding of vulnerability for stimulant abuse, and will potentially lead to better prevention and treatment interventions. ..
  50. Dedicated High Performance Human Brain/Preclinical PET
    DEAN WONG; Fiscal Year: 2004
    ..abstract_text> ..
  51. RISK MARKERS FOR DEMENTIA AFTER STROKE
    David Nyenhuis; Fiscal Year: 2004
    ..They state that refinement in our knowledge of mechanisms and causes for dementia in stroke patients may lead to an improvement in prevention and treatment strategies. ..
  52. GREAT LAKES REGIONAL NODE
    CHARLES SCHUSTER; Fiscal Year: 2004
    ..In summary we believe that the GLRN has a very strong research team, the administrative infrastructure to manage the program, and enthusiastic CTPs anxious to participate in the NIDA CTN. ..
  53. THE ROLE OF PEUTZ JEGHER GENE IN APOPTOSIS
    Junying Yuan; Fiscal Year: 2005
    ..We will also search for evidence of apoptosis inhibition in the polyps regions of the intestinal samples from Peutz-Jegher patients. ..
  54. Epidemiology of Prescription Drug Abuse in the United States
    SEAN MCCABE; Fiscal Year: 2007
    ..It will help identify risk factors for substance abuse. Most importantly, the findings will provide guidance for the prevention, assessment, and treatment of prescription drug abuse. [unreadable] [unreadable]..
  55. QUANTITATIVE FUNCTION IN MOTOR NEURON DISEASE
    Eric Sorenson; Fiscal Year: 2004
    ..This will become increasingly important as our population ages, increasing demands for medical and social resources. ..
  56. Nonmedical Prescription Drug Use among College Students
    SEAN MCCABE; Fiscal Year: 2005
    ..Findings from this research will have important implications for the understanding of the epidemiology, prevention and treatment of prescription drug abuse. ..
  57. 2005 Gordon Conference on Catecholamines
    David Sulzer; Fiscal Year: 2005
    ..abstract_text> ..
  58. Neuroadaptations underlying the transition to addiction.
    Osnat Ben Shahar; Fiscal Year: 2006
    ..Together, these experiments will illuminate some of the changes in dopaminergic function that underlie the transition to compulsive drug-use. ..
  59. Pressure-Based Pharmacological Alcoholism Treatments
    DARYL DAVIES; Fiscal Year: 2005
    ..These agents can form the bases of novel prevention and treatment strategies for alcoholism and alcohol abuse. ..
  60. LONG-TERM LORAZEPAM USE AND ACUTE TOXICITY IN THE AGED
    Nunzio Pomara; Fiscal Year: 2005
    ..index of brain white matter organization) contribute most strongly to the acute effects of lorazepam on cognitive/motor performance or postural sway in elderly individuals receiving long-term lorazepam treatment for GAD? ..
  61. NALTREXONE BLOCKADE OF NMDA
    John Krystal; Fiscal Year: 2002
    ..Thus, the blockade of the rewarding effects of ketamine by naltrexone may provide insight into an important mechanism underlying the psychopharmacology of ethanol and the treatment of alcoholism. ..
  62. Regulation of adult human oligodendrocyte progenitors
    Steven Goldman; Fiscal Year: 2008
    ..abstract_text> ..
  63. IMAGING DOPAMINE RELEASE/ENDOCRINE CHANGES IN ALCOHOLISM
    DEAN WONG; Fiscal Year: 2004
    ..If the initial D2 receptor deficits are exacerbated by alcohol abuse one can envision a positive feedback loop hard to break. ..
  64. Racial Disparities in Older Adults: Impact of Medicare Part D
    Joseph T Hanlon; Fiscal Year: 2010
    ....
  65. P33ING1 IN CELLULAR SENESCENCE AND ORGANISIMAL AGING
    Junying Yuan; Fiscal Year: 2003
    ..These works will illustrate the role of p33ING1 in mediating cellular senescence in culture and organismal aging in vivo. ..
  66. Prescription Drug Abuse Among College Students
    SEAN MCCABE; Fiscal Year: 2005
    ....